OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.…
OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company
OS Therapies (NYSEAMERICAN: OSTX) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4 employees.
The shares were at 0.8030 USD on 20 November 2026, down 58.6% over 52 weeks. Its 52-week range is 0.5800 USD to 2.250 USD: the price is 64.3% below the high and 38.4% above the low.
Its market capitalisation is 42.00M USD.
OS Therapies reports return on equity of 471.7% and an operating margin of 0.0%.
Its debt exceeds its cash by 1.52M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 30 March 2027.